Ranolazine inhibits an oxidative stress-induced increase in myocyte sodium and calcium loading during simulated-demand ischemia

Journal of Cardiovascular Pharmacology

Volumn 51, Issue 5, 2008, Pages 443-449

  Zhang, Xiu Q ^a   Yamada, Shigeyuki ^a   Barry, William H ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Angina; Contracture; Flow cytometry; Free radicals; Ischemia; Sodium calcium exchange

Indexed keywords

2 [2 [4 (4 NITROBENZYLOXY)PHENYL]ETHYL]ISOTHIOUREA METHANESULFONATE; CALCIUM; CYANIDE; GLUCOSE; RANOLAZINE; REACTIVE OXYGEN METABOLITE; SODIUM; TIRON; 2 (2 (4 (4 NITROBENZYLOXY)PHENYL)ETHYL)ISOTHIOUREA METHANESULFONATE; 2-(2-(4-(4-NITROBENZYLOXY)PHENYL)ETHYL)ISOTHIOUREA METHANESULFONATE; ACETANILIDE DERIVATIVE; DIVALENT CATION; DRUG DERIVATIVE; ENZYME INHIBITOR; MONOVALENT CATION; PIPERAZINE DERIVATIVE; THIOUREA;

ANGINA PECTORIS; ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTURE; HEART MUSCLE ISCHEMIA; METABOLIC INHIBITION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RABBIT; SODIUM CALCIUM EXCHANGE; SODIUM CELL LEVEL; SODIUM CURRENT; SODIUM TRANSPORT; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; IN VITRO STUDY; METABOLISM;

ACETANILIDES; ANIMALS; CALCIUM; CATIONS, DIVALENT; CATIONS, MONOVALENT; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLOW CYTOMETRY; MYOCARDIAL ISCHEMIA; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PIPERAZINES; RABBITS; SODIUM; THIOUREA;

EID: 55949087203     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318168e711     Document Type: Article

References (39)

1. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. JAMA. 2004;291: 309-316.
2. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375-1382.
3. Rousseau MF, Pouleur H, Cocco G, et al. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol. 2005;95:311-316.
4. Stone PH, Gratsianskky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine. The ERICA trial. J Am Coll Cardiol. 2006;48:566-575.
5. Clark B, Wyatt KM, McCormac JG. Ranolazine increases active pyruvate dehydrogenase in perfused rat hearts: evidence for an indirect mechanism. J Mol Cell Cardiol. 1996;28:341-350.
6. MacInnes A, Fairman DA, Binding P, et al. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2003;93:26-32.
7. Antzelevitch C, Belardinelli L, Wu L, et al. Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J Cardiovasc Pharmacol Ther. 2004;9(Suppl 1):S65-S83.
8. Hammarstrom AKM, Gage PW. Hypoxia and persistent sodium current. Eur Biophys J. 2002;31:323-330.
9. Belardinelli L, Antzelevitch C, Fraser H. Inhibition of late (sustained/persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function. Eur Heart J. 2004;6(suppl 1):13-17.
10. Boston DR, Koyama T, Rodriguez-Larrain J, et al. Effects of angiotensin II on intracellular Ca2+ and contracture in metabolically inhibited cardiomyocytes. J Pharmacol Exp Ther. 1998;285:716-723.
11. Li F, Sugishita K, Su Z, et al. Activation of connexin-43 hemichannels can elevate [Ca2+]i and [Na+]i in rabbit ventricular myocytes during metabolic inhibition. J Mol Cell Cardiol. 2001;33:2145-2155.
12. Rodriguez-Larrain JM, Sharma P, Sugishita K, et al. Effects of endothelin 1 on cation concentrations and viability of ventricular myocytes during ATP depletion: assessment by flow cytometry. Anal Pharmacol. 2001;2:1-8.
13. 2+ concentrations. J Biol Chem. 2000;275:27838-27844.
14. Sugishita K, Su Z, Li F, et al. Gender influences [Ca2+]i during metabolic inhibition in myocytes overexpressing the Na+-Ca2+ exchanger. Circulation. 2001;104:2101-2106.
15. Sugishita K, Li F, Su Z, et al. Antioxidant effects of estrogen reduce [Ca2+]i during metabolic inhibition. J Mol Cell Cardiol. 2003;35: 331-336.
16. Kadono T, Zhang XQ, Srinivasan S, et al. CRYAB and HSPB2 deficiency increases myocyte mitochondrial permeability transition and mitochondrial calcium uptake. J Mol Cell Cardiol. 2006;40:783-789.
17. Su Z, Zou A, Nonaka A, et al. Influence of prior Na pump activity on pump and Na/Ca exchange currents in mouse ventricular myocytes. Am J Physiol. 1998;275:H1808-H1817.
18. Song Y, Shryock JC, Wagner S, et al. Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther. 2006;318:214-222.
19. Ma JH, Luo AY, Zhang PH. Effect of hydrogen peroxide on persistent sodium current in guinea pig ventricular myocytes. Acta Pharmacol Sin. 2005;26:828-834.
20. Watano T, Kimura J, Morita T, et al. A novel antagonist, no. 7943, of the Na+/Ca2+ exchange current in guinea-pig cardiac ventricular cells. Br J Pharmacol. 1996;119:555-563.
21. Na on [Ca2+]i transients in mouse ventricular myocytes. Biophys J. 2001;80:1230-1237.
22. Su Z, Bridge JHB, Philipson KD, et al. Quantitation of Na/Ca exchanger function in single ventricular myocytes. J Mol Cell Cardiol. 1999;31: 1125-1135.
23. Kohmoto O, Barry WH. Mechanism of protective effects of calcium channel blockers on energy deprivation contracture in cultured ventricular myocytes. J Pharmacol Exp Ther. 1989;248:871-878.
24. Barry WH, Peeters GA, Rasmussen CAF Jr, et al. The role of changes in [Ca2+]i in energy deprivation contracture. Circ Res. 1987;61:726-734.
25. Koyama T, Boston D, Ikenouchi H, et al. Inhibition of rigor and of sarcoplasmic reticulum Ca2+ cycling enhances survival of adult rabbit ventricular myocytes subjected to severe ATP depletion. Am J Physiol. 1996;271:H643-H650.
26. Chen Q, Vazquez EJ, Moghaddas S, et al. Production of reactive oxygen species by mitochondria. J Biol Chem. 2003;278:36027-36031.
27. Apstein CS, Grossman W Opposite initial effects of supply and demand ischemia on LV compliance. The ischemia-diastolic paradox. J Mol Cell Cardiol. 1987;19:119-128.
28. Quaife RA, Kohmoto O, Barry WH. Mechanisms of reoxygenation injury in cultured myocytes. Circulation. 1991;83:566-577.
29. Bers DM, Barry WH, Despa S. Intracellular Na+ regulation in cardiac myocytes. Cardiovasc Res. 2003;57:897-912.
30. Scholz W, Albus U, Linz W, et al. Effects of Na+/H+ exchange inhibitors in cardiac ischemia. J Mol Cell Cardiol. 1992;24:731-740.
31. Haigney MCP, Lakatta EG, Stern MD, et al. Sodium channel blockade reduces hypoxic sodium loading and sodium-dependent calcium loading. Circulation. 1992;90:391-399.
32. Barry WH. Na fuzzy space: does it exist and is it important in ischemic injury? J Cardiovasc Electrophysiol. 2006;17(Suppl 1):S43-S46.
33. Barry WH, Brooker JZ, Alderman EL, et al. Changes in diastolic stiffness and tone of the left ventricle during angina pectoris. Circulation. 1974;49: 255-263.
34. Mann T, Brodie BR, Grossman W, et al. Effect of angina on the left ventricular diastolic pressure-volume relationship. Circulation. 1977;55: 761-766.
35. Varma N, Morgan JP, Apstein CS. Mechanisms underlying ischemic diastolic dysfunction: relation between rigor, calcium homeostasis, and relaxation rate. Am J Physiol. 2003;284:H758-H771.
36. Tron C, Donohue TJ, Kern MJ. Normal coronary flow velocity patterns. In: Kern MJ, ed. Interventional Physiology Rounds: Case Studies in Coronary Pressure and Flow for Clinical Practice. New York, NY: Wiley-Liss; 1998:173-184.
37. Wang P, Fraser H, Lloyd SG, et al. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion. J Pharmacol Exp Ther. 2007;321: 213-220.
38. Fraser H, Belardinelli L, Wang L, et al. Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol. 2006;41:1031-1038.
39. Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Am J Cardiol. 1999;84:46-50.